Form 4: Amgen Director Omar Ishrak Acquires 665 Shares

Amgen Inc. Director Omar Ishrak acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Summary

• Director Omar Ishrak acquired 665 shares of Amgen Inc. (AMGN) common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs) granted under the company's 2009 Director Incentive Program.
• Following this transaction, the reporting person's total beneficial ownership increased to 7,358.7361 shares.
• The transaction was executed at a price of $0 per share as part of director compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine director compensation rather than a discretionary market purchase or sale.

Positives

• Increased equity alignment between the director and shareholders.
• Demonstrates continued commitment from a member of the board of directors.

Negatives

• None identified; this is a standard equity compensation event.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

Not applicable; this is a retrospective disclosure of an equity transaction.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to align board incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of RSU-based compensation for board members is consistent with standard corporate governance practices among large-cap pharmaceutical and biotech companies like Pfizer, Gilead, and AbbVie.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard board compensation structure.

Next Steps

• No future actions required by the reporting person other than ongoing compliance with Section 16 reporting requirements.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan